

RESPONSE TO RESTRICTION REQUIREMENT


According to the Restriction Requirement, the examiner has identified two patentably distinct inventions under 35 U.S.C. § 121, as follows:

- Group I: claim(s) 1-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3,8-diazabicyclo[3.2.1]oct-8-yl.
- Group II: claim(s) 1-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3,7,9-triazabicyclo[3.3.1]nonane.
- Group III: claim(s) 1-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3,8-diazabicyclo[3.2.1]oct-3-yl.
- Group IV: claim(s) 1-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3,9-diazabicyclo[3.3.1]non-9-yl.
- Group V: claim(s) 1-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3-oxa-7,9-diazabicyclo[3.3.1]non-9-yl.
- Group VI: claim(s) 1-4 and 6-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 8-azabicyclo[3.2.1]oct-8-yl.
- Group VII: claim(s) 1-4 and 6-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 8-azabicyclo[3.2.1]oct-3-yl.
- Group VIII: claim(s) 1-4 and 6-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3-oxa-7-azabicyclo[3.3.1]non-7-yl.
- Group IX: claim(s) 1-4 and 6-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3-oxa-9-azabicyclo[3.3.1]non-9-yl.

- Group X: claim(s) 1-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl.
- Group XI: claim(s) 1-18, drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is other than those specifically defined in Groups I-X.

In response to the Restriction Requirement, applicants hereby elect **Group X** (which corresponds to claims 1-18), drawn to the compounds, compositions process of preparing and method of use of the compounds of formula I where the bridged ring system is 3-oxa-7,9-diazabicyclo[3.3.1]non-7-yl, with traverse.


Applicants respectfully traverse the foregoing restriction requirement. The election is made with traverse, based on the following considerations. Groups X and III do form one single group of inventions within the meaning of R. 13.1 and R. 13.2 PCT. All compounds of these three groups relate to bridged piperazine derivatives. The difference is that the bridge is a residue CH₂-O-CH₂- (group X), vs. a residue CH₂-CH₂- (group III). Contrary to the examiners opinion, these two groups do not contain a significantly different chemical structure: starting from group III (ethenyl bridge) to arrive at group X means to insert one oxygen atom in the chain. The differences / similarities of these two groups are shown in the structural formula below:



It is further believed that a different US classification is not a reason under R. 13 PCT. Consequently, the fact that two or more sub classes require a search are not a reason for issuance of a restriction requirement. Accordingly, applicants respectfully request reconsideration and withdrawal of the foregoing restriction requirement.

Notwithstanding the foregoing traversal and to provide a complete response, applicants hereby elect Group X (which corresponds to claims 1-18).

The Restriction Requirement further includes a requirement that applicants elect a species. Applicants elect the following species (Example 109):



Applicants respectfully submit that claims 1-18 read on the elected Species.


Applicants respectfully submit that the present submission is fully responsive to the outstanding Restriction Requirement. Prompt substantive examination of all elected claims is respectfully requested.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.
220 Massachusetts Ave.
Cambridge, MA 02139

(617) 871-5027

Date: November 2, 2009



A handwritten signature in black ink, appearing to read "B. Williams", is written over a horizontal line.

Agent for Applicant
Reg. No. 59,494